Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm

Autor: Miguel-Angel Perales, Shuk Ying Chan, Genovefa A. Papanicolaou, Rachel M Hughes, Kimberly Woo, Dionysios Neofytos
Rok vydání: 2020
Předmět:
Zdroj: Medical Mycology, Vol. 58, No 8 (2020) pp. 1029-1036
Med Mycol
ISSN: 1460-2709
1369-3786
DOI: 10.1093/mmy/myaa008
Popis: We sought to describe the clinical experience of voriconazole as primary antifungal prophylaxis (AFP) in allogeneic hematopoietic cell transplant recipients (allo-HCTr). This was a single-center retrospective study of adult allo-HCTr (1 January 2014 to 31 December 2016) who received ≥two doses of voriconazole-AFP. Voriconazole-AFP was started on day +7 post-HCT and continued at least through day +60 post-HCT, or longer as clinically indicated. We reviewed the rate, reasons, and risk factors of voriconazole-AFP discontinuation until day-100 post-HCT. A total of 327 patients were included. Voriconazole-AFP was continued for a median of 69 days (mean: 57.9; range 1, 100): for a median of 90 days (mean :84; range 2, 100) in 180/327 (55%) in the standard-of-care (SOC) group and 20 days (mean :25.6 ; range 1, 89; P-value
Databáze: OpenAIRE